American College of Neuropsychopharmacology
|
This article is part of the Pharma_Portal project of Spinwatch. |
The American College of Neuropsychopharmacology (ACNP) is the 'nation's premier professional society in brain, behavior, and psychopharmacology research.' It describes itself as a non-profit, professional society dedicated to advancing the scientific understanding of and the dissemination of knowledge about neuropsychiatric disorders in order to advance their prevention and treatment.' [1]
Contents
Policies on Financial Disclosure & Conflicts of Interest (COI)
The ACNP has 'historically provided a venue at which the best scientists from academia, government, and industry have gathered to share, discuss, and debate their research'. To facilitate this, the College is funded by 'membership dues, royalties from publication sales, meeting registration fees, and grants from corporations or governmental agencies.'[2] It aims to eradicate potential real and perceived COIs by using 'firewalls' to 'protect the integrity of College operations and to prevent the influence of financial sponsors from penetrating decision making processes of the College.' [3]
Funding
On its website, the ACNP reports that in 2009 it received $3,264,003.00 in revenue from: corporate fees (30%); annual meetings registration (26%); industry grants (17%); royalty income (15%); member dues (26%); subscription income (3%); management fee income (1%); and other sources(1%).
Supporting corporation sustaining fees ranging from $25,000 to $50,000 came from: Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb Company; Dainippon Sumitomo Pharmaceuticals; Eli Lilly and Company; Forest Pharmaceuticals; GlaxoSmithKline; H Lundbeck A/S; Hoffman-LaRoche; Janssen Pharmaceutica; Johnson & Johnson; Memory Pharmaceuticals; Merck; Novartis; Otsuka America Pharmaceuticals; Pfizer; Sanofi-Aventis; Schering-Plough; Sepracor, Inc.; Shire Pharmaceuticals; Solvay; Takeda Pharmaceuticals; Targacept, Inc.; and Wyeth.
Alkermes; AstraZeneca; Eli Lilly & Company; H Lundbeck A/S; Merck; Novartis; Ortho-McNeil Janssen; Otsuka America Pharmaceuticals; Pfizer; Sanofi-Aventis; and Wyeth gave financial support (ranging from $15,000 to $71,720) for specific projects.[4]
Membership
Membership is by nomination only. Individuals who have been members for three years or more, Life Fellows and Life Members are eligible to nominate others.[5]
Journal
Neuropsychopharmacology is the ACNP's official publication. The international scientific journal 'focuses upon clinical and basic science contributions that advance our understanding of the brain and behaviour, especially as related to the molecular, cellular, physiological and psychological properties of agents acting within the central nervous system and the identification of the new molecular targets for the development of the next generation of drugs.'[6]
Press Policy
Members of the press are not allowed to attend the ACNP Annual Meeting unless invited as guests by members. The College issues approved press releases.[7]
Contact
- Address:
- American College of Neuropsychopharmacology
- 545 Mainstream Drive, Suite 110
- Nashville, TN 37228
- Phone: 615-324-2360
- Email: acnp@acnp.org
- Website: http://www.acnp.org/default.aspx
Notes
- ↑ ACNP.ACNP:About us. Accessed 30 January 2010.
- ↑ ACNP.ACNP:About us. Accessed 30 January 2010.
- ↑ ACNP.ACNP Financial Disclosure & COI Firewalls Accessed 30 January 2010.
- ↑ ACNP. ANCP Financial Disclosure & COI Firewalls. Accessed 30 January 2010.
- ↑ ACNP. ACNP Membership. Accessed 30 January 2010.
- ↑ ACNP. ACNP Neuropsychopharmacology.Accessed on 30 January 2010.
- ↑ ACNP. ACNP Media Policy. Accessed 30 January 2010.
